Healthpoint's Leg Ulcer Cell Therapy Hits Phase III Trial

Healthpoint Biotherapeutics, of Fort Worth, Texas, began a Phase III trial of its allogeneic living cell bioformulation, HP802-247, for venous leg ulcers. The study will assess wound closure with HP802-247 plus compression therapy over a period of 12 weeks.